Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Liquidia Technologies Announces Collaboration with Abbott to Develop siRNA Therapeutics

Abstract:
Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT® nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.

Liquidia Technologies Announces Collaboration with Abbott to Develop siRNA Therapeutics

Research Triangle Park, NC | Posted on January 7th, 2009

"Delivery has been the most significant hurdle to realizing the broad potential of siRNA therapeutics. We are very pleased to form a partnership with Abbott, which we hope will enable significant progress in addressing this problem," said Neal Fowler, Chief Executive Officer of Liquidia. "By combining Abbott's research and development capabilities with Liquidia's particle design and delivery expertise, we hope to enable the use of siRNA for therapy and provide more targeted, effective treatment options for cancer patients."

Under the terms of the agreement, Liquidia will provide Abbott with certain rights to PRINT technology for the development and commercialization of siRNA therapeutics. Financial terms were not disclosed.

About siRNA Therapeutics - Short interfering RNA (siRNA) are small, double stranded RNA molecules that selectively silence and regulate the activity of human genes through the process of RNA interference (RNAi). Since many diseases are caused by the inappropriate expression of certain genes, the ability to selectively silence disease-associated genes represents a novel and powerful method for treating disease. The primary challenge to achieving broad application of siRNA therapeutics is effective delivery of the molecules to target tissues and cell types.

####

About Liquidia Technologies, Inc.
Liquidia Technologies Inc. is a privately-held nanotechnology company that designs, develops, and manufactures precisely engineered particles and films for a variety of life and materials science applications. Within life sciences, Liquidia is focused on developing novel vaccines and Engineered Drug Therapies™ for nucleic acid delivery and inhaled therapeutics. The company was founded in 2004 on the discoveries of Professor Joseph DeSimone and colleagues at the University of North Carolina, Chapel Hill and is located in Research Triangle Park, North Carolina.

For more information, please click here

Contacts:
Liquidia Technologies
Elle Pishny
919-328-4361

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

The International Space Elevator Consortium (ISEC) is proud to announce the 2014 Space Elevator Conference! This annual event will be held at the Museum of Flight in Seattle, Washington from Friday, August 22nd through Sunday, August 24th August 19th, 2014

KaSAM-2014 International Conference (September 7-10, 2014, Kathmandu, Nepal) August 19th, 2014

Success in Intracellular Imaging of Cesium Distribution in Plants Used for Cesium Absorption August 19th, 2014

Electrical engineers take major step toward photonic circuits: Team invents non-metallic metamaterial that enables them to 'compress' and contain light August 19th, 2014

Nanomedicine

Graphene rubber bands could stretch limits of current healthcare, new research finds August 19th, 2014

Interaction between Drug, DNA for Designing Anticancer Drugs Studied in Iran August 17th, 2014

Scientists fold RNA origami from a single strand: RNA origami is a new method for organizing molecules on the nanoscale. Using just a single strand of RNA, this technique can produce many complicated shapes. August 14th, 2014

Iranian Scientists Stabilize Protein on Highly Stable Electrode Surface August 14th, 2014

Announcements

Сalculations with Nanoscale Smart Particles August 19th, 2014

Life on Mars? Implications of a newly discovered mineral-rich structure August 19th, 2014

Harris & Harris Group Letter to Shareholders on Website August 19th, 2014

Electrical engineers take major step toward photonic circuits: Team invents non-metallic metamaterial that enables them to 'compress' and contain light August 19th, 2014

Patents/IP/Tech Transfer/Licensing

AQUANOVA receives Technology Leadership Award 2014 FROST & SULLIVAN honors NovaSOL® Technology again August 12th, 2014

Blacktrace Holdings Ltd. to in-license PerkinElmer Technology August 8th, 2014

Silicene Labs Announces the Launch of Patent-Pending, 2D Materials Composite Index™ : The Initial 2D Materials Composite Index™ for Q2 2014 Is: 857.3; Founders Include World-Renowned Physicist and Seasoned Business and IP Professionals July 24th, 2014

UCF Nanotech Spinout Developing Revolutionary Battery Technology: Power the Next Generation of Electronics with Carbon July 23rd, 2014

Alliances/Partnerships/Distributorships

SouthWest NanoTechnologies Appoints Matteson-Ridolfi for U.S. Distribution of its SMW™ Specialty Multiwall Carbon Nanotubes August 13th, 2014

Could hemp nanosheets topple graphene for making the ideal supercapacitor? August 12th, 2014

On the frontiers of cyborg science August 10th, 2014

Like cling wrap, new biomaterial can coat tricky burn wounds and block out infection August 10th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE